1 ***Preventive chemotherapy coverage against Soil-transmitted helminthiasis***
2 ***among school age children in vertical versus integrated treatment***
3 ***approaches: Implications from coverage validation survey in Ethiopia***

4

5

6 Mekuria Asfaw^{1*}, Zerihun Zerdo¹, Chuchu Churko¹, Fikre Seife², Manaye Yihune³, Yilma
7 Chisha³, Abinet Teshome³, Birhanu Getachew⁴, Nebiyu Negussu²

8

9

10 ¹Collaborative Research and Training Centre for NTDs, Arba Minch University, Arba Minch,
11 Ethiopia,

12 ²Neglected Tropical Diseases, Federal Ministry of Health, Addis Ababa, Ethiopia,

13 ³College of Medicine and Health Science, Arba Minch University, Ethiopia,

14 ⁴Ethiopian Public Health Institute, Addis Ababa, Ethiopia

15

16

17 ***Corresponding author**

18 mak.asnakew23@gmail.com (MA)

19

20

21

22 Abstract

23 **Background:** Soil-transmitted helminths (STH) are widely distributed in Ethiopia with
 24 highest prevalence and burden. Since 2015 the country launched national deworming
 25 programme to control STH associated morbidity using mass treatment with
 26 Albendazole/Mebendazole. Data on routine coverage of Preventive chemotherapy (PC) are
 27 available at different level of the health system, however in some circumstances these reports
 28 are unreliable and evidence is lacking on validated treatment coverage against STH.

29 **Methodology:** A community-based cross-sectional study was conducted in ten districts of
 30 Ethiopia; from January to April 2019. A total of 8154 SAC (4100 males and 4054 females)
 31 were participated from randomly selected households. Data were analysed using SPSS
 32 software (IBM, version 25); then di-aggregated by gender, age and school attendance and
 33 presented in tables and graphs.

34 **Principal findings:** Albendazole/Mebendazole mass treatment coverage against STH among
 35 school-age children was found to be 71%. In vertical (school-based) treatment approach,
 36 4822(68.4%) were treated; whereas in integrated (community directed) approach, 963(86.9
 37 %) were treated. The treatment coverage among males was 2948(71.9%), while among
 38 females it was 2837(70%). Based on age the treatment coverage in the age group 10-14 years
 39 was 77%; which is higher than the coverage in age group 5-9 years was 64.4%. In addition,
 40 the treatment coverage in school attendant was 81%; which is higher than coverage non-
 41 enrolled children (28%). The main deworming site was school, 5223(91%). Moreover, the
 42 main reported reasons for not swallowing drugs were not attending school, 422(19.75%) and
 43 drugs were not given, 397(18.6%).

44 **Conclusions/significance:** Albendazole/Mebendazole mass treatment coverage against soil-
 45 transmitted helminths among school-age children was below the WHO recommendation
 46 (75%). Operational research is required to identify barriers for low coverage of ALB/MBD

among children who are non-enrolled school-age children. Further, a call for action is required from different stakeholders to improve treatment coverage of ALB/MBD.

Key words: PC; Coverage; STH; Albendazole/Mebendazole; SAC; NTDs

Author Summary

Neglected Tropical Diseases (NTDs) are a group of communicable diseases, which inequitably affect the world's poorest, marginalized, voiceless and powerless people. It is prevalent in areas with unsafe water, poor sanitation and hygiene. STH (ascariasis, hookworm, and trichuriasis), intestinal worms, are one of the common NTDs which are transmitted through contact with soil contaminated with human feces.

Globally, more than 4 billion people are at risk for STH and with over 1 billion are already infected. In Ethiopia, about 81 million people are at risk for STH infection. School age children and pre-school age children are highly affected by the diseases, and it causes anemia, vitamin A deficiency, stunting, malnutrition, impaired development, and intestinal obstruction.

As one of NTDS, ending STH can contribute to Ethiopia be on track of attaining universal health coverage (UHC). STH can be controlled, possibly eliminated by combined interventions of preventive chemotherapy with improved water, sanitation and hygiene (WASH). In Ethiopia, though remarkable attainments are made so far on controlling STH morbidity through mapping and scaling-up mass drug administration, still more work is required to increase coverage of PC and integration of PC with WASH to meet the national objectives of elimination or control of STH.

71 **Introduction**

72 Neglected tropical diseases (NTDs) are a group of diseases mainly affect poorest and
73 marginalized people living in rural and urban areas, primarily in tropical and subtropical
74 areas [1, 2]. Soil-transmitted helminthiasis (STH), one of the major Neglected Tropical
75 Diseases (NTDs), are a group of intestinal parasites consisting of *Ascaris lumbricoides*
76 (roundworms), *Trichuris trichiura* (whipworms), and Hook worm, are transmitted by faecal
77 contamination of soil, and prevalent in areas with lack of improved water, sanitation and
78 hygiene [3-4].

79 Globally, about two billion people are being estimated in developing countries that are
80 infected with one or more species of helminths [5]. In 2017, 1.9 million disability-adjusted
81 life years (DALYs) associated with STH infection worldwide are estimated [6, 7]. Ethiopia
82 has wide distribution, highest prevalence and burden of STH, which causes 873,500
83 disability-adjusted life-years (DALYs), annually which represent 1.9% of the total DALYs
84 lost due to all causes. In the country, about 81 million people are living in STH endemic
85 areas, of which 25.3 million are school-aged children [8, 9]. STH infections with moderate
86 and heavy intensity are associated with anemia, malnutrition, educational loss, and cognitive
87 deficits [10-12].

88 The World Health Organization (WHO) recommends preventive chemotherapy (PC) with
89 Albendazole (ALB) or Mebendazole (MBD) to control STH-related morbidity in
90 combination with other recommended interventions such as health education and
91 improvement of interventions such as hygiene, water and sanitation [5, 13]. WHO sets a
92 target of regular provision of anthelmintic treatment to cover at least 75% of school age
93 children in endemic area [14]. In 2017, more than 500 million SAC (69% of total SAC in
94 need) received PC for STH globally, with 73% of implementation units reaching 75%

95 effective coverage [15]. More than 596 million SAC in 101 countries were estimated in need
96 of PC for STH in 2017; 61 countries submitted reports on treatment [4].

97 Ending NTDs by 2030 is targeted in the Sustainable Development Goal 3 (target 3.3); with a
98 focus of equity and Universal Health Coverage (UHC) [16]. Thus, addressing NTDs
99 contributes for achievement of the vision of universal health coverage, which means that all
100 individuals and communities who are in need of the health services will be addressed without
101 suffering financial hardship [17].

102 Starting from the time when the first World health organization (WHO) road map for the
103 prevention and control of NTDs was issued in 2012, significant progress has been made in
104 terms of controlling STH [2]. In line with the WHO goal, Ethiopia sets a target to achieve a
105 minimum 75% coverage of Albendazole or Mebendazole in school and pre-school age
106 children that should be achieved by the country program by 2020 [9].

107 In fact, routine coverage data are available at different level of Ethiopian health system.
108 However, evidence is lacking on validated treatment coverage Albendazole or Mebendazole
109 against STH among school age children. These data are required for the following
110 programmatic purposes: First, determine treatment coverage of Albendazole or Mebendazole
111 in school and pre-school age children in vertical and integrated treatment approaches to
112 improve program planning of PC. Second, generate treatment coverage data, dis-aggregated
113 by gender, sex and school attendance. Third, identify the reasons for why some individuals
114 do not receive drugs. Additionally, it can also be used to identify main deworming sites of
115 drug distribution.

116

117

Materials and Methods

Study setting

Ethiopia is the second largest country by population in sub-Saharan Africa, and is home to over 85 million people in need of preventive treatment, has a much higher burden of these diseases than in other countries of sub-Saharan Africa. Since the launch of the first national master plan for NTDs in 2013, the Government of Ethiopia has been liaising with WHO and other partners to achieve its objectives [9, 18]. **Fig 1** shows the area where study was conducted.

Fig 1. Map of study area for coverage of Albendazole/Mebendazole in Ethiopia, 2019.

Study design and population

We conducted a community-based cross-sectional study in ten districts of Ethiopia (selected from sentinel site of Federal Ministry of Health); from January to April 2019. All selected school age children who were available during the survey were included in the study.

Sample size and Sampling technique

A total of 30 segments were randomly selected from each district. The name of kebeles, number of households and the number of segments to be involved were predetermined using survey builder method before going to field for data collection. From each selected segment, at least 16 randomly selected households were included in the survey. From each selected household, all SAC were involved in the survey. Segment means group of 50 households.

The sampling is performed using the [WHO Coverage Evaluation Guidelines for Preventive Chemotherapy](#) [16].

Data collection and Statistical analysis

The data were collected using Survey CTO software using smartphones. Data were cleaned and analyzed using an Excel spread sheet and SPSS software (IBM, version 25). Then, data were dis-aggregated by gender, age and school attendance; presented in tables and figures.

Measurements

Coverage rate is defined as:

$$\frac{\text{Total number of interviewed individuals that ingested the target drug}}{\text{Total number of interviewed individuals}} * 100 \%$$

[16].

Ethical considerations

Ethical permission was obtained from the Federal Ministry of Health. A letter of support outlining the aims and objectives of the survey was submitted from the FMOH to the Regional Health Bureaux and their respective local administrations. Before collecting the data, informed consent was obtained from household heads (HH). In addition, purpose of the survey was explained to HH, and interview was took place only if he or she agreed to sign on the digital consent form on the data collection tablet.

Results

Characteristics of study participants

A total of 8,446 SAC were eligible for the study. Out of these, 8154 participated in the study giving a response rate of 96.5%. Out of the interviewed SAC, 1108 were from districts with integrated approach; while 7046 were from districts with vertical approach. In addition, 7,840 (96.15%) and 314 (3.85%) were interviewed during the first and second visits, respectively.

Regarding socio-demographic characteristics of participants: 3939(48.31%) SAC were within age group of 5-9 years; the gender proportions of SAC showed male and female were almost equally involved in the survey; and almost all children (99.7%) were enrolled in primary or secondary (**Table 1**).

Table 1. Socio-demographic characteristics of SAC among selected districts of Ethiopia, 2019.

Variables	Categories	Frequency	%
Age (years)	5-9	3939	48.3
	10-14	4215	51.7
Gender	Female	4054	49.7
	Male	4100	50.3
School Attendance	No	1563	19.2
	Yes	6591	80.8
Educational level	Primary	6571	99.7
	Secondary	20	0.3
School type	Public	6441	97.7
	Private	138	2.1
	Religious	12	0.2

Albendazole/Mebendazole treatment coverage

The overall treatment coverage of Albendazole/Mebendazole against STH was found to be 71.0% (5785/8154) (**Fig 2**). Out of 7046 interviewed SAC in districts with non-integrated approach, 4822(68.4%) reported that they swallowed ALB/MBD for STH. Among 1108 interviewed SAC in districts with integrated approach, 963(86.9%) reported that they swallowed ALB/MBD against STH. Dis-aggregated data on treatment coverage of Albendazole by districts showed Guagusa had the highest (91.6%) coverage whereas Gura-Ferda had the lowest coverage (21.6%) (**Fig 2**).

Fig 2. Albendazole/Mebendazole treatment coverage among SAC in Ethiopia, 2019.

Albendazole/Mebendazole treatment status disaggregated by gender, age and school attendance

The proportion of STH treatment coverage among males was 2948(72%) while among females was 2837(70%). Treatment coverage in the age group (10-14) years was significantly higher than coverage in group (5-9) years old, ($\chi^2 = 170.57$, P-value <0.001). In addition, the treatment coverage in school attendant was higher than coverage non-enrolled children (**Table 2**).

Table 2. Albendazole/Mebendazole treatment coverage disaggregated by age, gender and school attendance in Ethiopia 2019, (N= 8,154).

Variables	<i>Swallowed ALB/MBD</i>			Pearson_ chi square (p_ value)
	Yes n (%)	No n (%)	Unknown n(%)	
Gender				
Female	2837(70.00)	1095(27.00)	122(3.00)	3.81(0.15)
Male	2948(71.90)	1042(25.4)	110(2.7)	
Age in years				
5-9	2534(64.4)	1246(31.6)	159(4.0)	170.57(0.001)
10-14	3251(77.1)	891(21.2)	73(1.7)	
School attendance				
Yes	5343(81.1)	1178(17.9)	70 (1.0)	
No	442(28.3)	959(61.4)	162(10.3)	
Heard on MDA				
Yes	5227(86.7)	783(13)	19(0.3)	
No	557(26.2)	1353(63.8)	213(10.0)	

Reasons for not swallowing ALB against STH

A total of 2137 (26.2%) children reported that they didn't receive STH treatment. The main reported reasons for not taking the medication were not attending school (n=422, (19.75%) and drugs was not given 397(18.6%) (**Table 3**).

198 **Table 3. Reasons for not swallowing Albendazole in selected districts of Ethiopia, 2019.**

Variables	Frequency	%
<i>Reasons for not swallowing ALB/MBD</i>		
Fear of side effects	136	6.36
Too sick	25	1.20
Not eaten break fast	5	0.23
Drug not given	397	18.60
No MDA	227	10.60
Not attending school	422	19.75
Absent at the time of MDA	246	11.51
Not living in village	52	2.42
Drugs run out	75	3.51
No definite reason	313	14.65
Bad rumors	26	1.21
Un aware about MDA	213	9.90

199

200

201

202

203

204

Treatment coverage of ALB/MBD in vertical versus integrated treatment approaches

The difference in treatment coverage of ALB/MBD was statistically different between the vertical and integrated approaches ($X^2 = 158.72$, $P = <0.001$) (Table 5).

Table 5. Treatment coverage of ALB/MBD in vertical Vs. integrated approaches, Ethiopia, 2019.

Treatment approach	Swallowed ALB/MBD			X^2	P-value
	Yes (%)	No (%)	Unknown (%)		
Vertical	4822(68.4)	2008(28.5)	216(3.1)	158.72	< 0.001
Integrated	963 (86.9)	129(11.6)	16(1.5)		

Mass drug administration distribution sites for ALB/MBD

The main site where children received the treatment was in school compound as evidenced by the high percentage value 5223(91%) shown in pie chart below (Fig 3).

Fig 3. Place of deworming using Albendazole/Mebendazole in Ethiopia, 2019.

Discussion

This study in ten districts of Ethiopia shows Albendazole/Mebendazole mass treatment against soil-transmitted helminthiasis among school-age children in integrated versus vertical treatment approaches result in overall treatment coverage of 71%. In vertical treatment approach 68.4% (4822/7046) were treated; while in integrated approach 86.9 % (963/1108) individuals were treated. The overall treatment coverage in our study is lower than the WHO's and Ethiopian target; which is to achieve at least 75% coverage of PC by 2020 either through annual or biannual treatment of SAC [9, 19]. The overall coverage in our study is slightly higher than the a global coverage of 68.8% in 2017; which is presented in the WHO fact sheet [15]. In addition, a policy platform on treatment coverage with ALB/MBD of different countries using 2016 WHO data showed 31 countries achieved <75% coverage including Ethiopia, while 57 countries achieved 75% and above treatment coverage [19].

Moreover, WHO report in 2017 showed 36 countries reached 75% coverage for SAC [15]. In our study, the treatment coverage in integrated approach is 87%; it is greater than the WHO recommendation (75%). This result is consistent with a study conducted in Mali where 87% coverage was reported [20]. The possible explanation for higher coverage of ALB/MBD in integrated approach than the vertical approach could be due to its effectiveness to deliver the drugs to those who are in need of drugs at community level.

In our study, gender dis-aggregated data showed the proportion of STH treatment coverage among males was 2948(72%); while among females it was 2837(70%), which means the coverage among males is slightly higher for males. However, this finding dis-agree with a data obtained from 16 countries in which the coverage for females was slightly higher than the coverage for males [21]. Moreover, the coverage of ALB/MBD in this survey is lower than coverage survey of Ethiopia conducted in 2015 [22].

The treatment coverage in school attendant was 81%; which is higher than coverage non-enrolled children (28%). This finding is differ from the coverage survey result of Ethiopia in 2015; which is 92.95% for school attendant while 52.2% for non-enrolled children [22]. The possible explanation for the lower coverage of ALB/MBD among non-enrolled children in this study could be exclusive school based deworming platform is inadequate to address those children who are out of school.

Moreover, our study showed the treatment coverage in the age group 10-14 years was significantly higher than coverage in group 5-9 years. Probably the higher coverage in this age group is due to these children have better chance of attending school. In addition, the main reported reasons for not taking treatment were not attending school and treatment was not given. These reasons can be explained as attending school can increase in association

with accessing drugs for those who are in needs. In this case evidence is lacking to discuss over this finding.

The study has the following limitations: First, purposive selection and small of districts make difficult to generalize the findings to national level. Second, identifying barriers associated with low treatment coverage of ALB/MBD among non-enrolled school-age children could be difficult with descriptive cross-sectional study. However, as strength we identified possible reasons for not swallowing the drugs; and this study showed validated treatment coverage of ALB/MBD at national level.

Conclusions

The study showed Albendazole/Mebendazole mass treatment coverage against soil-transmitted helminths among school-age children was found to be 71%, which is below the WHO recommendation (75%). In addition, coverage survey should be performed in many districts of Ethiopia to validate routine reports. Moreover, operational research is required to identify factors with low coverage of school AIB/MBD among non-enrolled school-age children. Further, a call for action is required from different stakeholders to improve treatment coverage of ALB/MBD.

Funding: This study is made possible by the generous support of Federal Ministry of Health.

Competing interests: Authors declared that there are no conflicts of interests.

Acknowledgements

Authors would like to thank NTD focal persons in each of the woredas involved in the study; community guiders who were directing households in each segment of the kebeles; study participants, and staff in College of Medicine and Health Sciences who participated in the data collection process.

Author's contributions

MA drafted the original manuscript. MA, ZZ, CC, MY, YC and AT contributed in data analysis. MA, ZZ, CC, FS, MY, YC, AT, BG and NN involved in the conception, design & interpretation of the data. All authors read and approved the final manuscript.

References

1. World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. World Health Organization; 2010. Available from: https://www.who.int/neglected_diseases/resources/9789241564090/en/
2. World Health Organization. Ending the neglect to attain the sustainable development goals: A road map for neglected tropical diseases 2021–2030. World Health Organization; 2020. Available from: https://www.who.int/neglected_diseases/Ending-the-neglect-to-attain-the-SDGs--NTD-Roadmap.pdf?ua=1
3. Montresor A, Trouleau W, Mupfasoni D, Bangert M, Joseph SA, Mikhailov A, Fitzpatrick C. Preventive chemotherapy to control soil-transmitted helminthiasis averted more than 500 000 DALYs in 2015. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2017 Oct 1;111(10):457-63. Available from: <https://academic.oup.com/trstmh/article-abstract/111/10/457/4811853>
4. World Health Organization. Uniting to combat NTDs. Available from: <https://unitingtocombatntds.org/reports/5th-report/soil-transmitted-helminths-progress/>
5. World Health Organization. Soil-transmitted helminthiasis: eliminating as public health problem soil-transmitted helminthiasis in children: progress report 2001-2010 and strategic plan 2011-2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/44804/9789241503129_eng.pdf

6. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. *Parasites & vectors*. 2014 Dec 1;7(1):37. Available from: <https://link.springer.com/article/10.1186/1756-3305-7-37>
7. Pullan RL, Brooker SJ. The global limits and population at risk of soil-transmitted helminth infections in 2010. *Parasites & vectors*. 2012 Dec 1;5(1):81. Available from: <https://link.springer.com/article/10.1186/1756-3305-5-81>
8. Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017 Sep 16;390(10100):1260-344. Available from: <https://www.sciencedirect.com/science/article/pii/S014067361732130X>
9. Federal Democratic Republic of Ethiopia Ministry of Health. Second Edition of Ethiopia National Master Plan For Neglected Tropical Diseases. Addis Ababa, Ethiopia. 2016. Available from: <https://www.afro.who.int/publications/second-edition-national-neglected-tropical-diseases-master-plan-ethiopia-2016>
10. Owada K, Nielsen M, Lau CL, Clements AC, Yakob L, Magalhaes RJ. Measuring the effect of soil-transmitted helminth infections on cognitive function in children: systematic review and critical appraisal of evidence. In *Advances in parasitology* 2017 Jan 1 (Vol. 98, pp. 1-37). Academic Press. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0065308X17300477>
11. Welch VA, Ghogomu E, Hossain A, Awasthi S, Bhutta ZA, Cumberbatch C, Fletcher R, McGowan J, Krishnaratne S, Kristjansson E, Sohani S. Mass deworming to

improve developmental health and wellbeing of children in low-income and middle-income countries: a systematic review and network meta-analysis. The Lancet Global Health. 2017 Jan 1;5(1):e40-50. Available from:

<https://www.sciencedirect.com/science/article/pii/S2214109X1630242X>

12. Pabalan N, Singian E, Tabangay L, Jarjanazi H, Boivin MJ, Ezeamama AE. Soil-transmitted helminth infection, loss of education and cognitive impairment in school-aged children: A systematic review and meta-analysis. PLoS neglected tropical diseases. 2018 Jan;12(1). Available from:

<https://journals.plos.org/plosntds/article/file?type=printable&id=10.1371/journal.pntd.0005523>

13. World Health Organization. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. World Health Organization; 2006. Available from: <https://www.cabdirect.org/cabdirect/abstract/20073104734>

14. World Health Organization. Helminth control in school-age children: a guide for managers of control programmes. World Health Organization; 2011. Available from: https://apps.who.int/iris/bitstream/handle/10665/44671/9789241548267_eng.pdf

15. World Health Organization. Schistosomiasis and soil-transmitted helminthiasis: numbers of people treated in 2017. Weekly Epidemiological Record. 2018 Dec 14; 93(50):681-92. Available from: <https://apps.who.int/iris/bitstream/handle/10665/276934/WER9350-681-692.pdf>

16. Assembly G. United Nations: Transforming our world: The 2030 agenda for sustainable development. Tech. Rep. 1; 2015. Available from: <https://www.icnl.org/resources/library/transforming-our-world-the-2030-agenda-for-sustainable-development>

- 348 **17.** World Health Organization. Universal health coverage: WHO fact sheet. World
349 Health Organization; 2019.
- 350 **18.** World Health Organization. Crossing the billion: Preventive chemotherapy for
351 neglected tropical diseases. World Health Organization; 2017
- 352 **19.** Freeman MC, Akogun O, Belizario Jr V, Brooker SJ, Gyorkos TW, Imtiaz R,
353 Krolewiecki A, Lee S, Matendechero SH, Pullan RL, Utzinger J. Challenges and
354 opportunities for control and elimination of soil-transmitted helminth infection
355 beyond 2020. PLoS neglected tropical diseases. 2019 Apr;13(4). Available from:
356 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459486/>
- 357 **20.** Dembélé M, Bamani S, Dembélé R, Traoré MO, Goita S, Traoré MN, Sidibe AK,
358 Sam L, Tuinsma M, Toubali E, MacArthur C. Implementing preventive chemotherapy
359 through an integrated national neglected tropical disease control program in Mali.
360 PLoS neglected tropical diseases. 2012 Mar;6(3). Available from:
361 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308933/>
- 362 **21.** Cohn DA, Kelly MP, Bhandari K, Zoerhoff KL, Batcho WE, Drabo F, Negussu N,
363 Marfo B, Goepogui A, Lemoine JF, Ganefa S. Gender equity in mass drug
364 administration for neglected tropical diseases: data from 16 countries. International
365 health. 2019 Sep 2;11(5):370-8.). Available from:
366 <https://academic.oup.com/inthealth/article/11/5/370/5371211>
- 367 **22.** Federal Ministry of Ethiopia, Scistosomiasis Control Initiative, Imperial College
368 London, Evidence action and EPHI. Coverage Validation Survey. Ethiopia; 2015.

369

%coverage